Table 1.
Univariate analysis of main characteristics of kidney recipients presenting with BK virus nephropathy by CMV coinfection.
| Variable | No Coinfection n (%) 14 (61) |
Coinfection n (%) 9 (39) |
p Value |
|---|---|---|---|
| Male sex | 10 (71) | 5 (55) | 0.656 |
| Median age (IR) | 53 (20–69) | 51 (31–64) | 0.543 |
| Diabetes mellitus | 5 (36) | 5 (55) | 1 |
| Hepatitis C virus | 2 (14) | 0 | 0.52 |
| HIV | 0 | 0 | |
| Induction therapy | 13 (93) | 8 (89) | 1 |
| Antilymphocyte globulin | 7 (50) | 5 (55) | |
| Basiliximab | 6 (43) | 3 (33) | |
| Immunosuppressive regimen | 0.534 | ||
| Cs + MMF + PDN | 1 | 0 | |
| FK + MMF + PDN | 8 | 5 | |
| mTOR + FK + PDN | 5 | 3 | |
| mTOR + MMF + PDN | 0 | 1 | |
| Prior transplantation | 6 (43) | 1 (11) | 0.122 |
| Double transplant (kidney and páncreas) | 2 (14) | 3 (33) | 0.383 |
| Median days from TX to BK nephropathy (1st, 3rd quartiles) | 401 (93–870) | 364 (301–508) | 0.544 |
| Postransplantation hemodialysis | 1 (0.7) | 1 (11) | 1 |
| Urologic reintervention | 6(43) | 3 (33) | 1 |
| Nephrostomy | 2 (14) | 2 (22) | 0.654 |
| Acute allograft rejection | 5 (36) | 6 (66) | 0.432 |
| Median BK viral load in blood (1st, 3rd quartiles) | 709,853 (18,866–915,000) | 3,636,210 (349,273–7,060,361) | 0.018 |
CNI: calcineurin inhibitor, CMV: cytomegalovirus; HIV: human immunodeficiency virus, MMF: mycophenolate, mTOR: mammalian target of Rapamycin, PDN: prednisone, TX: transplantation, FK: Tacrolimus, Cs: Cyclosporine.